Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United StatesResearch in context

• Główni autorzy: Ayodeji Adegunsoye (Autor), Rachel Baccile (Autor), Thomas J. Best (Autor), Victoria Zaksas (Autor), Hui Zhang (Autor), Rasika Karnik (Autor), Bhakti K. Patel (Autor), Anthony E. Solomonides (Autor), William F. Parker (Autor), Julian Solway (Autor)
• Format: Książka
• Wydane: Elsevier, 2023-09-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Summary: Background: Pulmonary fibrosis is characterized by lung parenchymal destruction and can increase morbidity and mortality. Pulmonary fibrosis commonly occurs following hospitalization for SARS-CoV-2 infection. As there are medications that modify pulmonary fibrosis risk, we investigated whet...